Luciano Costa, MD, PhD, Discusses Use of Daratumumab Plus KRd in Multiple Myeloma

Video

Luciano Costa, MD, PhD, spoke about the potential application of daratumumab, carfilzomib, lenalidomide, and dexamethasone for multiple myeloma in a real-world setting.

At the 2021 American Society of Hematology Annual Meeting, Luciano Costa, MD, PhD, associate director for Clinical Research at O’Neal Comprehensive Cancer Center, discussed how the primary end point results of the MASTER trial (NCT03224507) can be used in the real-world treatment setting to guide selection of daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone for patients with multiple myeloma. 

Transcript:

What we learned from this study is that we have been treating myeloma the same way, with decisions made mostly on transplant eligibility. The reality is patients respond very differently, and I think different paths of response require different actions. It is the first steppingstone for response-adaptive therapy. The way our group wants to go is to optimize quadruple therapy, perhaps with a longer induction. For patients who [are] minimal residual disease [MRD] negative already after induction, we need to ask the de-escalation questions. Maybe those people can do very well, even without transplant, and we want to try to answer them in a randomized way. Conversely, for patients who remain MRD positive after transplant, we need to engage new agents here. We would like to compare transplant followed by conventional care with transplant followed by an anti–B-cell maturation antigen [BCMA] agent. There are many ways this can be framed and designed, but I think we need to embrace the notion that response after quadruple therapy sought out patients who are candidates for de-escalation and patients who are candidates for escalation therapy.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content